Analysis
Oura launched its IPO roadshow with a price range of $40 to $44 per share, targeting an initial market capitalization of $12.8 billion to $14.1 billion and a fully diluted valuation of approximately $15.62 billion, with trading expected to begin on Nasdaq under ticker OURA the week of September 28, according to MobiHealthNews and Traders Agency.
What's New Since Pulse's Last Coverage
Pulse previously reported that Oura had set terms to raise up to $2.2 billion, with 36.5 million of the 50 million shares on offer coming from existing shareholders rather than the company itself. This update adds the specifics that filing left open: the $40-$44 price range, a confirmed trading start date, and Oura's first disclosed revenue figure -- $1.21 billion over the nine months ending in June, up 74% from the same period a year earlier.
The Math Behind The Insider Payday
At the $42 midpoint, Oura itself is offering 13.5 million shares for roughly $532.6 million in net proceeds to the company, while existing stockholders are offering the remaining 36.5 million shares. Forerunner Ventures, Oura's second-largest shareholder, plans to sell its full 9.3% stake -- about 28.7 million shares -- for roughly $1.2 billion before fees, by far the largest single payday of the offering. That structure confirms the dynamic Pulse flagged when terms first became public: this IPO is primarily a liquidity event for early backers rather than a capital raise to fund Oura's own growth.
The One New Data Point That Changes The Read
The 74% year-over-year revenue growth figure, disclosed for the first time in this amended filing, is a genuinely strong number for a hardware-and-subscription business at Oura's scale, and it gives public-market investors a real growth metric to weigh against the insider-payday structure -- a company growing revenue at that rate has a stronger case for its $15.6 billion valuation than the share-sale mechanics alone would suggest.
What To Watch
Trading beginning the week of September 28 puts Oura's debut in the same fall IPO window Pulse has tracked closely, including Electra Therapeutics' rockier-than-expected first day. Whether Oura's stock holds near its offer price or follows Electra's pattern of a strong indicated open followed by a weaker close will be an early read on whether public investors are pricing wearable health-data platforms on growth, on the insider-selling structure, or on both.
